Graduate Program in Neuroscience, University of British Columbia, Canada.
Department of Psychology, University of British Columbia, Canada.
Psychoneuroendocrinology. 2021 Aug;130:105273. doi: 10.1016/j.psyneuen.2021.105273. Epub 2021 May 18.
Perinatal depression (PND) affects 15% of mothers. Selective serotonin reuptake inhibitors (SSRIs) are currently the first-line of treatment for PND but are not always efficacious. Previously, we found significant reductions in plasma tryptophan concentrations and higher hippocampal proinflammatory cytokine, IL-1β levels, due to maternal SSRI treatment. Both inflammation and tryptophan-kynurenine metabolic pathway (TKP) are associated with SSRI efficacy in individuals with major depressive disorder (MDD). TKP is divided into neuroprotective and neurotoxic pathways. Higher metabolite concentrations of the neurotoxic pathway are associated with depression onset and implicated in SSRI efficacy. Metabolites in TKP were investigated in a rodent model of de novo postpartum depression (PPD) given treatment with the SSRI, fluoxetine (FLX). Dams were administered corticosterone (CORT) (40 mg/kg, s.c.), and treated with the SSRI, fluoxetine (FLX) (10 mg/kg, s.c.), during the postpartum for 22 days after parturition. Plasma TKP metabolite concentrations were quantified on the last day of treatment. Maternal postpartum CORT increased neurotoxic metabolites and co-enzyme/cofactors in dams (3-hydroxykynurenine, 3-hydroxyanthranilic acid, vitamin B2, flavin adenine dinucleotide). The combination of both CORT and FLX shifted the neuroprotective-to-neurotoxic ratio towards neurotoxicity. Postpartum FLX decreased plasma xanthurenic acid concentrations. Together, our data indicate higher neurotoxic TKP expression due to maternal postpartum CORT treatment, similar to clinical presentation of MDD. Moreover, maternal FLX treatment showed limited efficacy to influence TKP metabolites, which may correspond to its limited efficacy to treat depressive-like endophenotypes in the postpartum. Overall suggesting changes in TKP may be used as a biomarker of de novo PPD and antidepressant efficacy and targeting this pathway may serve as a potential therapeutic target.
围产期抑郁症(PND)影响 15%的母亲。选择性 5-羟色胺再摄取抑制剂(SSRIs)目前是 PND 的一线治疗药物,但并不总是有效。先前,我们发现由于母亲服用 SSRIs,血浆色氨酸浓度显著降低,海马促炎细胞因子 IL-1β水平升高。炎症和色氨酸-犬尿氨酸代谢途径(TKP)都与 SSRIs 在患有重度抑郁症(MDD)的个体中的疗效相关。TKP 分为神经保护和神经毒性途径。神经毒性途径的代谢物浓度较高与抑郁发作有关,并与 SSRIs 的疗效有关。在给予 SSRIs 氟西汀(FLX)治疗的新生产后抑郁(PPD)啮齿动物模型中研究了 TKP 中的代谢物。在产后第 22 天,给予皮质酮(CORT)(40mg/kg,皮下注射)和 SSRI 氟西汀(FLX)(10mg/kg,皮下注射)治疗。在最后一天的治疗时定量测定血浆 TKP 代谢物浓度。产后母体 CORT 增加了母体的神经毒性代谢物和辅酶/辅因子(3-羟基犬尿氨酸、3-羟基邻氨基苯甲酸、维生素 B2、黄素腺嘌呤二核苷酸)。CORT 和 FLX 的联合作用使神经保护-神经毒性比向神经毒性转变。产后 FLX 降低了血浆黄尿酸浓度。总的来说,我们的数据表明,由于产后母体 CORT 治疗,TKP 的表达更高,类似于 MDD 的临床表现。此外,母体 FLX 治疗对影响 TKP 代谢物的效果有限,这可能与其在产后治疗抑郁样表型的疗效有限相对应。总体而言,TKP 的变化可能被用作新生 PPD 和抗抑郁药疗效的生物标志物,靶向该途径可能成为一种潜在的治疗靶点。